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Objective: To investigate the in vitro activity of a range of anti-anaerobe antimicrobials against non-Bacteroides fragilis 
group anaerobic Gram-negative bacilli isolated in Europe. 
Methods: Isolates from 15 laboratories in 13 countries were identified by conventional methods. The MlCs of 20 
antibiotics were determined by an agar dilution method. 
Results: There were 488 Prevotella spp., 174 fusobacteria, 69 Porphyromonas spp., 33 Bacteroides spp., 28 Bilophila 
wadsworthia and 16 Campylobacter spp. isolates, one Sutterella wadsworthensis isolate and four unidentified isolates. 
Penicillin resistance (and diminished susceptibility to piperacillin) was most common in Prevotella spp. and Bilophila 
wadsworthia but was also seen in many other species. All isolates, except three of Bilophila wadsworthia, were 
susceptible to amoxycillin/clavulanate. Most isolates were susceptible to cefoxitin (except Bilophila wadsworthia) and 
all were susceptible to the carbapenems. Clinafloxacin was the most active quinolone, followed by trovafloxacin and 
then sparfloxacin. Most fusobacteria were inherently resistant to the macrolides, as expected, but resistance to 
macrolides and a ketolide in other species was uncommon. Most Fusobacteriurn varium isolates were resistant to 
clindamycin, but resistance to clindarnycin in all other species was rare. Tetracycline resistance was common but this 
did not affect the glycylcyclines. There was one isolate of Bacteroides putredinis resistant to chloramphenicol, and three 
isolates, a Bacteroides ureolyticus isolate, the Sutterella wadsworthensis isolate and one of the unnamed isolates, were 
rnetronidazole resistant. Rifampicin was active against most Prevotella and Porphyromonas spp., but not against many 
other genera. 
Conclusions: Penicillin resistance has increased in Europe among non-Bacteroides fragilis anaerobic Gram-negative 
bacilli, much of it due to P-lactamase. Acquired resistance to other p-lactams, macrolides and rifampicin has not 
significantly increased, and chloramphenicol and metronidazole are unaffected. However, resistance to tetracycline is 
common. The new compounds, a ketolide (HMR 3647), the glycylcyclines and clinafloxacin, are highly active. 
Key words: Anerobic Gram-negative bacilli, antimicrobial resistance, p-lactams, macrolides, ketolides, quinolones, 
glycylcyclines 
INTRODUCTION 
Anaerobic Gram-negative bacilli other than the Buc- 
teroidesfragilis group have been shown to be involved in 
both dental and medical infections, either alone, as is 
often the case with Fusobacterium necrophorum [l], or 
mixed with other species [2,3]. Some ofthese anaerobic 
species have intrinsic resistance to recognized anti- 
anaerobic drugs, e.g. Fusobacterium species to macrolides 
[4], but acquired resistance has been recognized for 
some time, at least to some groups of antibiotics such 
as tetracycline and p-lactams [5,6]. However, resistance 
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to other commonly used antimicrobial agents such as 
metronidazole and imipenem is rare [7], and many 
laboratories no longer see the necessity for identi- 
fication or sensitivity testing of anaerobes. It is therefore 
important to monitor independently, resistance to both 
recognized and new antimicrobial agents with activity 
against anaerobic bacteria, as a guide to their empirical 
use. 
In this study we have collected anaerobic Gram- 
negative bacih other than the Bacteroides fragilis group 
from both dental and medical laboratories in Europe, 
and tested the susceptibility of the isolates to 20 
antimicrobial agents. 
MATERIALS AND METHODS 
Antimicrobial agents 
The agents tested, as powders of known potency, were 
gifts of the manufacturers. Penicillin and clavulanic acid 
were supplied by SmithKline Beecham, Harlow, UK, 
piperacillin, tazobactam and tetracycline by Wyeth 
Laboratories, Maidenhead, UK, the glycylcyclines 
CL344677 and CL331928 by Wyeth-Ayerst, Pearl 
River, NY, USA, cefoxitin and imipenem by Merck 
Sharp & Dohme Ltd, Hoddesdon, UK, meropenem by 
Zeneca, Macclesfield, UK, dinafloxacin by Parke 
Davis, Eastleigh, UK, sparfloxacin and metronidazole 
by Rh6ne-DPC Europe, Antony, France, trovafloxacin 
by Pfizer, Sandwich, UK, the ketolide HMR 3647 
and roxithromycin by Hoeschst-Marion-Roussel Anti- 
Infectives, Romainville, France, clindamycin by 
Pharmacia & Upjohn Ltd, Milton Keynes, UK, and 
clarithromycin by Abbott Laboratories Ltd, Maiden- 
head, UK. Amoxycillin, rifampicin and chloram- 
phenicol were purchased from Sigma-Aldrich Co. Ltd, 
Poole, UK. 
Susceptibility breakpoints recommended by the 
NCCLS for anaerobic bacteria [8] were: penicillin 
50.5 mg/L, amoxycillin/clavulanate 54/2  mg/L, 
cefoxitin 5 16 mg/L, chloramphenicol 5 8  mg/L, 
clindamycin 5 2 mg/L, imipenem and meropenem 5 4 
mg/L, metronidazole 5 8  mg/L, piperacillin 532  
mg/L, piperacillin/tazobactam 532/4 mg/L, tetra- 
cycline 5 4  mg/L, and trovafloxacin 5 2  mg/L. Those 
adapted from recommendations for aerobic bacteria 
[9] were: rifampicin 51  mg/L and clarithromycin 
5 2  mg/L. The breakpoints used for antimicrobials 
tested for which there are no recommendations were: 
sparfloxacin and clinafloxacin 5 2  mg/L, based on those 
for trovafloxacin and as previously published [lo], 
CL344677 and CL331928 5 4  mg/L (as tetracycline), 
and roxithromycin and HMR 3647 5 2  mg/L (as 
clarithromycin) . 
Organisms 
Each of 15 laboratories in 13 European countries 
collected consecutive clinical isolates, associated with 
infection, of anaerobic Gram-negative bacilli, excluding 
those belonging to the Bacteroidesfragilis group, between 
January 1995 and June 1996. We included the Carnpylo- 
bacter species submitted, since they were submitted as 
anaerobes and grew in our anaerobic conditions, 
although the genus is characteristically micro-aero- 
philic. The isolates were sent to St Thomas’ Hospital, 
London, where they were identified [ l l ]  by conven- 
tional tests [12,13] and stored at -70°C in 7% glycerol 
broth. 
Determination of minimum inhibitory concentrations 
(MICs) 
MICs were determined by an agar dilution method 
[8,13]. The antibiotics were incorporated, in doubling 
dilution steps, in 20 mL Brucella agar (BBL 4311086 
Becton Dickinson, Oxford, UK) supplemented with 
5% laked horse blood, 1 mg/L vitamin K1 and 5 mg/L 
hemin and also 0.3% formate/fumarate for Bacteroides 
ureolyticus and Campylobacter spp. and 1% pyruvate for 
Bilophila wadsworthia. 
AmoxyciUin/clavulanate was tested in a 2:l ratio, 
while piperacillin and tazobactam were tested with a 
futed concentration of tazobactam (4 mg/L). Isolates 
were grown on Fastidious Anaerobe Agar (Lab 90, 
LAB M, Bury, UK) containing 10% horse blood and 
incubated for 48 h in an anaerobic cabinet. The cells 
were suspended in Brain Heart Infusion broth (CM225 
Oxoid, Basingstoke, UK) and diluted to give a final 
inoculum of lo5  colony-forming units per spot. The 
antibiotic plates were prereduced overnight in 
anaerobic conditions at ambient temperature, and 
then inoculated with a multipoint inoculator (Denley, 
Burgess Hill, UK) and incubated at 37°C for 48 h in 
an anaerobic cabinet containing 10% H2, 10% C02 
and 80% Nz. Bacteroidesfragilis ATCC 25285 (NCTC 
9343) and a previously described internal control Prevo- 
tella intermedia 98.13 [14] were included with all tests. 
The interpretation of trailing endpoints, seen parti- 
cularly with hsobacteria and p-lactams, was facilitated 
by overlay with triphenyl-tetrazolium chloride (TTC) 
agar to detect viable cells [15]. 
P-Lactamase production 
Production of 0-lactamase was detected by spreading 
fresh (24-48 h) cultures on filter paper moistened with 
a 500 mg/L solution of nitrocefin (Oxoid, Basingstoke, 
UK). All isolates of Fusobacterium necrophorum, isolates 
of Fusobacterium nucleaturn with penicillin MICs 20.5 
mg/L, and isolates of Prevotella species with penicillin 
MICs 0.5-1 mg/L, were tested. 
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Analysis of results 
MICs were entered in a microcomputer, and a 
computer program developed from that described by 
Shannon and Phillips [16] was used to analyze the data. 
Organisms in the intermediate susceptibility category 
are, for convenience, generally referred to as resistant, 
but information on the proportion of isolates in the 
intermediate (I) and resistant (R) categories is also given. 
RESULTS 
Eight hundred and thrteen isolates belonging to species 
of Gram-negative bacilli other than the Bacteroides 
jagilis group were received for the study. Over half 
(488) belonged to the genus Prevotella, 174 were 
Fusobacterium spp. and 69 were Porphyromonas species. 
The remainder were Bacteroides spp. (33), Bilophila 
wadsworthia (28), Campylobacter spp. (16), Sutterella 
wadsworthensis (1) and four isolates that remain un- 
named despite extended biochemical tests. These 
unnamed isolates were included in the analysis of 
results, as they fitted the definition of the study. The 
number of isolates, the range of MICs and MIC5o and 
MIC90 for each species are listed in Tables 1-4. 
P-Lactams 
There were penicillin-resistant isolates in all species of 
Prevotella, but the rate of resistance was highest in 
Prevotella bivia (68% R, 2% I), Prevotella melaninogenica 
(60% R), Prevotella denticola (41% R, 15% I) and 
Prevotella oralis (53% R). The majority of isolates of 
Porphyromonas were susceptible, with only two isolates 
of Poyhyromonas levii resistant (penicillin MIC 4 mg/L). 
All but one isolate of Bilophila wadsworthia were resistant 
to penicillin. All Bacteroides ureolyticus isolates were 
susceptible, as was the single isolate of Bacteroides 
putredinis, but the remaining six isolates of Bacteroides 
spp., including all five isolates of Bacteroides splanchnicus, 
were resistant. Penicdlin was highly active against all 
ftsobacteria, with the exception of five of the seven 
isolates of Fusobacterium mort@nrm and occasional isolates 
of Fusobacterium nucleatum. Three of nine isolates of 
Campylobacter gracilis were resistant but the remaining 
campylobacters were susceptible. 
The results for piperacillin correlated well with 
those of penicillin (r =0.86), and isolates resistant to 
piperacan were also resistant to penicillin (Figure 1). 
However, because of the difference in breakpoint, the 
apparent overall resistance rate was lower for piper- 
acillin than for penicillin. 
All of the isolates in the study were susceptible to 
amoxycillin/clavulanate, except for three isolates of 
Bilophila wadsworthia (MIC 8 mg/L). Most isolates of 
Prevotella spp., Porphyromonas spp. and Bacteroides spp. 
0.001 0.004 0.016 0.06 0.25 1 4 16 64 
penicillin MIC (ma) 
Figure 1 Correlation of penicillin and piperacillin MICs 
for 813 isolates of non-Bacteroider~agi~~r anaerobic Gram- 
negative bacilli (NCCLS breakpoints: penicillin 0.5 mg/L, 
piperacillin 32 mg/L). 
were susceptible to 4mg/L of tazobactam alone, as 
were occasional isolates of the other species, and, 
consequently, for these isolates, there was no growth 
in the tests for the combination with piperacillin. All 
isolates with tazobactam MICs >4 mg/L were suscep- 
tible to the combination, with the exception of three 
isolates of Campylobacter gracilis. Cefoxitin was active 
against all isolates except for the majority of isolates of 
Bilophila wadsworthia, the one Sutterella wadsworthensis 
isolate and one of the unnamed isolates. Although all 
the fusobacteria were susceptible to cefoxitin, isolates 
of Fusobacterium mortijrum and Fusobacterium varium 
were much less susceptible than the other species. Both 
carbapenems were active against all isolates but mero- 
penem was slightly more active than imipenem, parti- 
cularly against Fusobacterium spp., Bilophila wadsworthia, 
Bacteroides ureolyticus and Campylobacter spp. Of the 
isolates tested for P-lactamase production, 0 of 29 
Fusobacterium necrophorum isolates, two of 10 Fuso- 
bacterium nucleatum isolates and 13 of 25 Prevotella spp. 
isolates with penicillin MICs 0.5-1 mg/L (Prevotella 
bivia 3/5, Prevotella denticola 6/7, Prevotella disiens 2/2, 
Prevotella intermedia 019, Prevotella loescheii 1 /1 and 
Prevotella sp. 1/1) were positive. 
Quinolones 
Clinafloxacin was the most active of the quinolones 
tested, and all isolates in the study were susceptible 
(MICs 1 2  mg/L), with the exception of one isolate of 
Prevotella bivia and two of Prevotella denticola, all with 
clinafloxacin MICs of 4 mg/L and all submitted by the 
same laboratory. Trovafloxacin, which was about four- 
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Table 5 Distribution of non-Bacteroidesfragilis group anaerobic Gram-negative bacllli among specimens received 5om 
Merent European regions and laboratories 
Scandinavia” United Kingdom Central Europeb Southern/eastern Europe‘ 
4 5 7 1 5  1 6 12 10 13 14 3 2 8 9 1 1  
Prevotella bivia/disiens 
Prevotella intermedidspp. 
Porphyromonas spp. 
Fusobacterium nucleaturn 
Fusobacterium spp. 
Bilophila wadsworthia 
Bacteroides spp. 
Campylobacter spp. 
Sutferella wadsworthensis 
Unnamed 
Total 
51 32 11 8 28 1 42 1 6 2 
11  49 54 35 49 37 6 31 9 12 3 1 3  6 
5 6 9  1 0 1 3  5 8 8  3 1 1  
5 14 8 20 3 12 18 45 1 
1 15 2 6 6 9  5 4 
3 1  1 15 
5 7 6 14 
2 7  1 5  1 
1 2  1 
1 
63 117 98 52 68 118 12 111 54 30 62 5 9 5 9 
3 5 
1 
~~ ~ ~ ~~ _ _ ~  ~ 
aDenmark, Norway, Finland, Sweden; bGermany, Belgium, The Netherlands; ‘France, Italy, Spain, Bulgaria, Poland. 
fold less active than clinafloxacin, was also active against 
the majority of isolates, but 18% of isolates of Prevotella 
bivia were resistant, as were occasional isolates of 
Campylobacter rectus, other Prevotella species and Bilopkila 
wadsworthia and the one isolate of Fusobacterium russii 
(trovafloxacin MICs 4-8 mg/L). Porphyromonas levii 
(trovafloxacin MICs 1-4 mg/L) was the least suscep- 
tible species overall. Sparfloxacin was 2-4-fold less 
active than trovafloxacin and, in addition to those 
isolates resistant to trovafloxacin, there were resistant 
isolates of many other species. 
Macrolides, clindamycin and ketolides 
The majority of Prevotella and Porphyromonas species 
were susceptible to the ketolide HMR 3647, with the 
exception of two isolates of Prevotella bivia (HMR 3647 
MIC 8 and >32mg/L) and one of Porphyrornonas 
asacckarolytica (HMR 3647 MIC > 32 mg/L). These 
three isolates were also resistant to clindamycin and the 
macrolides. One isolate of Prevotella intermedia was 
resistant to clindamycin and the macrolides but was 
susceptible to HMR 3647. Most Bacteroides species, 
other than Bacteroides ureolyticus, and Campylobacter 
species were susceptible to HMR 3647 and the macro- 
lides, but MICs were higher for these than for other 
susceptible species: all but one isolate of Campylobacter 
gracilis were susceptible to clindamycin. Isolates of 
Bilopkila wadsworthia and Bacteroides ureolyticus were 
susceptible to clindamycin, moderately susceptible to 
HMR 3647, but resistant to clarithromycin and roxi- 
thromycin. The majority of fusobacteria were resistant 
to HMR 3647, clarithromycin and roxithromycin, 
but there were differences between the species-all 
Fusobacterium mortijirum and Fusobacterium varium isolates 
were highly resistant, as were the majority of the 
Fusobacterium nucleaturn isolates. Fusobacteriurn necrophonrm 
isolates were more susceptible to all three, although 
the MICs were close to the breakpoint or often above 
it, particularly for roxithromycin. Most fusobacteria 
were susceptible to clindamycin, with the exception of 
five of the seven Fusobacterium varium isolates and one 
unnamed Fusobacterium sp. isolate. 
Tetracycline, glycylcyclines and miscellaneous 
antimicrobials 
There were tetracycline-resistant isolates among all 
Prevotella and Porpkyromonas species, with the exception 
of Porphyromonas gingivalis, but there were differences 
between the species. Over 50% of isolates of Prevotella 
bivia, Prevotellu disiens, Prevotella loesckeii, Prevotella 
melaninogenica, Porphyromonas levii and the unnamed 
Prevotella species were resistant, but only small numbers 
of the other species were resistant. There were also 
small numbers of resistant isolates in most of the 
other species included in the study, but all isolates 
of Fusobacterium mortijerum, Fusobacterium varium and 
Campylobacter rectus were susceptible to tetracycline. 
The glycylcycline CL344677 was slightly more active 
than CL331928, but both were active against all isolates 
in the study. 
All isolates were susceptible to chloramphenicol, 
except for one isolate of Bacteroides putredinis, and three 
isolates were resistant to rnetronidazole, one Bacteroides 
ureolyticus isolate, which was the least susceptible 
species, the Sutterella wadsworthensis isolate and one of 
the unnamed isolates which was closely related to 
Campylobacter gracilis. Rifampicin was highly active 
against Prevotella and Porphyromonas species, with only 
occasional strains of Prevotella bivia and one isolate of 
Porphyromonas gingivalis being resistant. However, the 
activity of rifampicin was poor against the other genera 
tested. All isolates of Fusobacterium morti$erum, Fuso- 
K i n g  e t  a l :  S u s c e p t i b i l i t y  o f  a n a e r o b i c  G r a m - n e g a t i v e  b a c i l l i  4 1 5  
bacterium varium and Bilophila wadsworthia were resistant, 
as were most isolates of Bacteroides ureolyticus. 
The numbers of isolates of species or groups of 
species from the individual participating laboratories 
are listed in Table 5, and the laboratories are grouped 
in geographic areas of Europe. The mix of species from 
dental laboratories (numbers 1 and 14), the majority of 
isolates being Prevotella species other than bivia or 
disiens, Fusobucterium nucleaturn and Porphyromonas species, 
differed from that of the medical laboratories. This 
accounted for differences in overall resistance rates, 
particularly for penicillins and macrolides. Taking 
this into account, there was little difference between 
the regions in sensitivity of individual species to all 
antibiotics, with the exception of the macrolides, 
clindamycin and the ketolide against Porphyromonas 
spp., for which the small number of isolates from 
southern and eastern Europe were consistently more 
resistant than those from other areas (Figure 2) .  
DISCUSSION 
Most studies of the antimicrobial susceptibility of 
anaerobic bacteria report on serial isolates from clinical 
material and thus concentrate on the more common 
species, and aggregate results for less common isolates 
[17,18], and there is therefore little information on the 
susceptibility of less commonly isolated individual 
species-hence the emphasis of our study. However, it 
is worth noting that among the non-Bacteroides fvagilis 
group Gram-negative bacilli, as with anaerobes as a 
whole, some species are rarely isolated. The difference 
in distribution of species between medical and dental 
laboratories was not unexpected, but its effect on 
resistance rates has not often been noted. 
We confirmed the high level of resistance to 
penicillin, which we noted as increasing in London 
almost two decades ago [5], and to piperacillin among 
Prevotella species which has been reported recently by 
others [19,20]. Much of this resistance is reversed by 
amoxycillin/clavulanate and thus is conventionally 
considered to be due to 0-lactamases, and indeed it 
has also been shown that this is often the case [20]. 
However, many of the Prevotella isolates that we 
examined are susceptible to p-lactamase inhibitors 
alone, although b-lactamase-positive strains are often 
less susceptible than (3-lactamase-negative strains [5], 
and the majority of the isolates in this study were 
susceptible to tazobactam 4 mg/L alone. In contrast, 
fusobacteria (except Fusobacterium mort@rum, as we 
noted in 1981 [5]) were susceptible to penicillin and 
piperacillin when difkulties in reading endpoints were 
resolved by the use of TTC overlay [15]. None of our 
isolates of Fusobacterium necrophorum and only 2% of the 
Fusobacterium nucleatum isolates (penicillin MICs 4, 64 
mg/L) produced P-lactamase-by inference, isolates 
with penicillin MICs <0.5 mg/L, which we did not 
test, were p-lactamase negative. This finding was in 
contrast with that of Jacobs et a1 [20], who found that 
7% of Fusobacterium necrophorum isolates and 24% of 
Fusobacterium nucleatum isolates were p-lactamase positive 
in the European isolates included in their study. 
Although we did not test all isolates for (3-lactamase 
production, our penicillin resistance rates, linked with 
amoxycillin/clavulanate susceptibility rates, for Prevotella 
clindamycin 
- 
A B C D  
and Porphyromonas spp. are broadly compatible with the 
rates of p-lactamase production reported by Jacobs et 
al [20]. Overall, the NCCLS penicillin breakpoint 
(0.5 mg/L) reflects P-lactamase production better than 
does the ampicillin breakpoint (4 mg/L). 
Resistance rates for quinolones are difficult to 
calculate in view of the general absence of breakpoints 
related to anaerobes, and of inconsistencies when they 
do exist. Taking into account the different intrinsic 
activities of the quinolones that we examined, acquired 
resistance appears to be rare, as it appeared to be in the 
Bacteroidesfragilis group in our earlier study [21]. 
Apart from the well-known resistance of some 
species, particularly fusobacteria, resistance to macro- 
lides and the ketolide was uncommon. The addition of 
CO:! to the gas mixture may have led to higher than 
roxithromycin HMR 3647 
is 
A B C D  A B C D  
expected macrolide and ketolide MICs. However, there 
was usually a clear distinction between sensitive and 
resistant isolates, and only for small numbers of isolates 
were the results close to the breakpoints where mis- 
interpretation could occur. Only occasional isolates 
Figure 2 Distribution of MICs of clindamycin, 
roxithromycin and HMR 3647 for 69 Porphyromonas spp. 
from Scandinavia (A), UK (B), central Europe (C) and 
southedeastern Europe (D). See Table 5 for countries 
included in groups. 
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appeared to have acquired resistance to clindamycin- 
12 of the 813 isolates (1.5%) had clindamycin MICs 
>2 mg/L, compared with virtually none in London in 
1981 [5] and in contrast to around 9% in 1992 for the 
Bacteraides jagilis group in Europe [21]. However, 
tetracycline resistance was almost as prevalent among 
PrevotelZa spp. as it was for the Bacteroides fragilis group 
in our earlier study in Europe [21]. Strikingly, there was 
no cross-resistance between tetracycline and the two 
glycylcyclines. Interestingly, we reported 28% tetra- 
cycline resistance among 265 non-Bacteroides fragilis 
group anaerobic Gram-negative bacilli isolated in 
London in the 1970s [5]. 
Virtually all of our isolates were susceptible to the 
rarely used chloramphenicol and to the commonly used 
metronidazole. In contrast, rifampicin resistance was 
more common, but was probably intrinsic-a fact 
already well recognized for Fusobacterium mortiferum 
and Fusobacterium varium [22]. 
We conclude that in Europe the prevalence of 
P-lactamase production has increased, and therefore so 
has resistance to penicillin, amoxycillin and piper- 
acilhn (although this does not affect all species), but that 
the addition of clavulanate or tazobactam usually 
reverses this resistance, albeit as an inhibitor of either 
P-lactamase production or of growth. 
Tetracycline resistance has also increased, but all 
isolates were susceptible to the glycylcyclines. The two 
glycylcyclines tested may not be further developed, but 
as examples of the class give important information. 
There is resistance to the macrolides, in species other 
than the fusobacteria, and the new ketolide is more 
active and has inhibitory activity against a wide range 
of species. Our suggestion that resistance to new and old 
agents should be monitored is, we believe, vindicated. 
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